3rd Generation GD-2 Chimeric Antigen Receptor and ICaspase Suicide Safety Switch, Neuroblastoma, GRAIN
GRAIN
Autologous Activated T-Cells Transduced with a 3rd Generation GD-2 Chimeric Antigen Receptor and ICaspase9 Safety Switch Administered to Patients with Relapsed or Refractory Neuroblastoma (GRAIN)
2 other identifiers
interventional
11
1 country
2
Brief Summary
Subjects that have relapsed or refractory neuroblastoma are invited to take part in this gene transfer research study. We have found from previous research that we can put a new gene called a chimeric antigen receptor (CAR) into T cells that will make them recognize neuroblastoma cells and kill them. In a previous clinical trial, we used a CAR that recognizes GD2, a protein found on almost all neuroblastoma cells (GD2-CAR). We put this gene into T cells and gave them back to patients that had neuroblastoma. The infusions were safe and in patients with disease at the time of their infusion, the time to progression was longer if we could find GD2 T cells in their blood for more than 6 weeks. Because of this, we think that if T cells are able to last longer, they may have a better chance of killing neuroblastoma tumor cells. Therefore, in this study we will add new genes to the GD2 T cells that can cause the cells to live longer. These new genes are called CD28 and OX40. The purpose of this study will be to determine the highest dose of iC9-GD2-CD28-OX40 (iC9-GD2) T cells that can safely be given to patients with relapsed/refractory neuroblastoma. In other clinical studies using T cells, some investigators found that giving chemotherapy before the T cell infusion can improve the amount of time the T cells stay in the body and therefore the effect the T cells can have. This is called lymphodepletion and we think that it will allow the T cells we infuse to expand and stay longer in the body, and potentially kill cancer cells more effectively. The chemotherapy we will use for lymphodepletion is a combination of cyclophosphamide and fludarabine. Additionally, to effectively kill the tumor cells, it is important that the T cells are able to survive and expand in the tumor. Recent studies have shown that solid tumors release a substance (PD1) that can inhibit T cells after they arrive into the tumor tissue. In an attempt to overcome the effect of PD1 in neuroblastoma we will also give a medication called pembrolizumab.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for phase_1
Started Aug 2013
Longer than P75 for phase_1
2 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
March 28, 2013
CompletedFirst Posted
Study publicly available on registry
April 2, 2013
CompletedStudy Start
First participant enrolled
August 1, 2013
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2015
CompletedStudy Completion
Last participant's last visit for all outcomes
October 1, 2030
ExpectedFebruary 24, 2025
February 1, 2025
2.3 years
March 28, 2013
February 21, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Dose limiting toxicities at 6 weeks post T cell infusion
We will measure and assess the adverse events to find the maximum tolerated dose of iC9-GD2 T cells and the safety profile of iC9-GD2 T cells.
6 weeks after infusion of the last dose of iC9-GD2 T cells to all patients on the study
Secondary Outcomes (3)
To evaluate the expansion and persistence of 3rd generation iC9-GD2 T cells
15 years
Time to progression of disease
15 years
Change in serum cytokine and chemokine levels
15 years
Study Arms (3)
iC9-GD2 T Cells - fresh - CLOSED
EXPERIMENTALThe cells will be given IV over 5-10 minutes. There is a possibility for additional doses of iC9-GD2 T cells.
iC9-GD2 T Cells - frozen - CLOSED
EXPERIMENTALThe cells will be given IV over 5-10 minutes. There is a possibility for additional doses of iC9-GD2 T cells.
iC9-GD2 T cells,Cytoxan,Fludara,Keytruda
EXPERIMENTALFresh T cells will be given IV over 5-10 mins. There is a possibility for additional doses of iC9-GD2 T cells.
Interventions
Subjects will receive the iC9-GD2 T cells through an IV over 5 to 10 minutes. Subjects will receive one of the following dose levels (cells/m2): * Dose Level 1 = 1 x 10\^7 * Dose Level 2 = 1 x 10\^8 * Dose Level 3 = 2 x 10\^8 Six weeks after the infusion, patients will have a disease re-evaluation. If the disease has not gotten worse AND they have not had a severe side effect caused by the infusion of the iC9-GD2 T cells, the subject may be eligible to receive up to 2 additional doses of T cells. Each dose will be at the same dose level as the first infusion, if available, and separated by at least 6 weeks.
For subjects who will receive a fresh T cell product: * Dose Level 1 = 1 x 10\^8 * Dose Level 2 = 1.5 x 10\^8 * Dose Level 3 = 2 x 10\^8 Six weeks after the infusion, patients will have a disease re-evaluation. If the disease has not gotten worse AND they have not had a severe side effect caused by the infusion of the iC9-GD2 T cells, the subject may be eligible to receive up to 2 additional doses of T cells. Each dose will be at the same dose level as the first infusion, if available, and separated by at least 6 weeks.
Cyclophosphamide (500 mg/m2/day x 2 days, for patients \<12 kg = 16.7 mg/kg/day x 2 days)
Fludarabine (30 mg/m2/day x 3 days, for patients \<12 kg = 1 mg/kg/day x 3 days)
Pembrolizumab (2 mg/kg on Day -1 and on Day 21).
For subjects who will receive a fresh T cell product: * Dose Level 1 = 1.5 x 10\^8 * Dose Level 2 = 2 x 10\^8 Six weeks after the infusion, patients will have a disease re-evaluation. If the disease has not gotten worse AND they have not had a severe side effect caused by the infusion of the iC9-GD2 T cells, the subject may be eligible to receive up to 2 additional doses of T cells. Each dose will be at the same dose level as the first infusion, if available, and separated by at least 6 weeks.
Eligibility Criteria
You may qualify if:
- PROCUREMENT
- High risk neuroblastoma with persistent or relapsed disease
- Life expectancy of at least 12 weeks
- Karnofsky/Lansky score of 60% or greater
- Absence of HAMA prior to enrollment (only in patients that have been previously treated with murine antibodies)
- Informed consent and assent (as applicable) obtained from parent/guardian and child
- TREATMENT:
- High risk neuroblastoma with persistent or relapsed disease
- Life expectancy of at least 12 weeks
- Karnofsky/Lansky score of 60% or greater
- Patients must have an ANC greater than or equal to 500, platelet count greater than or equal to 20,000
- Pulse Ox greater than or equal to 90% on room air
- AST and ALT less than 5 times the upper limit of normal
- Total bilirubin less than 3 times the upper limit of normal
- Serum creatinine less than 3 times upper limit of normal. Creatinine clearance is needed for patients with creatinine greater than 1.5 times upper limit of normal
- +6 more criteria
You may not qualify if:
- PROCUREMENT:
- Rapidly progressive disease
- History of hypersensitivity to murine protein containing products
- TREATMENT:
- Rapidly progressive disease
- Currently receiving other investigational drugs
- History of hypersensitivity to murine protein containing products
- History of cardiomegaly or bilateral pulmonary infiltrates on chest radiograph or CT. However, patients with cardiomegaly on imaging may be enrolled if they have an assessment of cardiac function (i.e., ECHO or MUGA) within 3 weeks of starting protocol therapy that is within normal limits. Additionally, patients with bilateral pulmonary infiltrates on imaging may be enrolled if the lesions are not consistent with active neuroblastoma (i.e., negative on functional imaging with PET or MIBG, or by pathologic assessment).
- Evidence of tumor potentially causing airway obstruction
- Patients who are pregnant, lactating, or unwilling to use birth control
- Patients currently receiving immunosuppressive drugs such as corticosteroids, tacrolimus or cyclosporine
- Patients previously experienced severe toxicity from cyclophosphamide or fludarabine
- Severe previous toxicity from pembrolizumab or other PD-1 targeted antibody
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Baylor College of Medicinelead
- Center for Cell and Gene Therapy, Baylor College of Medicinecollaborator
- The Methodist Hospital Research Institutecollaborator
- Solving Kids' Cancercollaborator
- The Evan Foundationcollaborator
- National Cancer Institute (NCI)collaborator
- Kids Cancer Research Foundationcollaborator
Study Sites (2)
Houston Methodist Hospital
Houston, Texas, 77030, United States
Texas Children's Hospital
Houston, Texas, 77030, United States
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Andras A. Heczey, MD
Baylor College of Medicine
Study Design
- Study Type
- interventional
- Phase
- phase 1
- Allocation
- NON RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Assistant Professor
Study Record Dates
First Submitted
March 28, 2013
First Posted
April 2, 2013
Study Start
August 1, 2013
Primary Completion
December 1, 2015
Study Completion (Estimated)
October 1, 2030
Last Updated
February 24, 2025
Record last verified: 2025-02